PAHCHIGH SIGNALOPPORTUNITY10-K

PAHC completed a major $297.5 million acquisition from Zoetis while achieving exceptional financial performance with net income surging nearly 1,900% and operating income doubling.

The company successfully executed a transformational acquisition that significantly expanded their product portfolio and geographic reach, evidenced by the jump from 750 to 800 product lines and expansion from 80+ to 90 countries. This strategic move, funded through debt financing, appears to be paying immediate dividends with dramatically improved profitability metrics suggesting strong operational leverage and integration success.

Comparing 2025-08-27 vs 2024-08-28View on EDGAR →
FINANCIAL ANALYSIS

PAHC's financial performance was exceptional, with net income exploding from $2.4M to $48.3M and operating income more than doubling to $110.5M, demonstrating powerful operational leverage. The balance sheet reflects the major acquisition impact with total assets growing 39% to $1.4B and inventory surging 67% to $444.4M, while total liabilities increased 48% to $1.1B primarily from acquisition financing. Despite higher interest expense from the debt-funded acquisition, the company's ability to generate such dramatic profit improvements while successfully integrating a major acquisition signals strong execution and growth momentum.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+1897.7%
$2.4M$48.3M

Net income grew 1897.7% — bottom-line growth signals improving overall business health.

Total Deposits
Balance Sheet
-1026.3%
-$532K-$6.0M

Deposits declined 1026.3% — significant outflows warrant immediate investigation into funding stability.

Operating Income
P&L
+107.2%
$53.3M$110.5M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Inventory
Balance Sheet
+67.1%
$265.9M$444.4M

Inventory surged 67.1% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Total Liabilities
Balance Sheet
+48.2%
$725.5M$1.1B

Liabilities grew 48.2% — significant increase in debt or obligations, assess impact on financial flexibility.

Interest Expense
P&L
+47.2%
$12.7M$18.7M

Interest expense surged 47.2% — significant debt increase or rising rates materially impacting earnings.

Current Liabilities
Balance Sheet
+43.8%
$204.1M$293.5M

Current liabilities surged 43.8% — significant near-term obligations; verify ability to meet short-term debt.

Total Assets
Balance Sheet
+38.6%
$982.2M$1.4B

Asset base grew 38.6% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+34.9%
$601.0M$810.6M

Current assets grew 34.9% — improving short-term liquidity or inventory/receivables build.

Accounts Receivable
Balance Sheet
+34.5%
$169.5M$228.0M

Receivables surged 34.5% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

LANGUAGE CHANGES
NEW — 2025-08-27
PRIOR — 2024-08-28
ADDED
As of August 22, 2025 there were 20,367,574 shares of the registrant s Class A common stock, par value $ 0.0001 per share, and 20,166,034 shares of the registrant s Class B common stock, par value $ 0.0001 per share, outstanding.
We market approximately 800 product lines in approximately 90 countries to approximately 4,500 customers.
For discussion regarding the impact of armed conflicts between Israel and Hamas (and potential broader military conflict in the region) and between Russia and Ukraine on our financial results, see Part II, Item 7, Management s Discussion and Analysis of Financial Condition and Results of Operations.
Acquisition In April 2024, the Company entered into a Purchase and Sale Agreement (the Purchase Agreement ) with Zoetis Inc., a Delaware corporation ( Zoetis ) to acquire Zoetis s medicated feed additive ( MFA ) portfolio, certain water-soluble products and related assets (the Acquisition ).
On October 31, 2024, the Company completed the Acquisition at a purchase price of approximately $297.5 million ($286.5 million, as adjusted, net of cash acquired), subject to certain further adjustments set forth in the Purchase Agreement.
+7 more — sign up free →
REMOVED
As of August 23, 2024, there were 20,337,574 shares of the registrant s Class A common stock, par value $ 0.0001 per share, and 20,166,034 shares of the registrant s Class B common stock, par value $ 0.0001 per share, outstanding.
We market approximately 750 product lines in over 80 countries to approximately 4,200 customers.
For discussion regarding the impact of the ongoing armed conflicts between Israel and Hamas and between Russia and Ukraine on our financial results, see Part II, Item 7, Management s Discussion and Analysis of Financial Condition and Results of Operations.
Business Segments We manage our business in three segments Animal Health, Mineral Nutrition, and Performance Products each with its own dedicated management and sales team, for enhanced focus and accountability.
Our companion animal development pipeline includes an early-stage atopic dermatitis compound, a potential treatment for mitral heart valve disease in dogs, a pain product and two oral care products.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
IRIXHIGHIRIX demonstrated a dramatic operational turnaround with revenue surging 283% wh...
2026-04-02
CSAIHIGHCSAI underwent a dramatic financial transformation with revenue growing 271% to ...
2026-03-31
PLMKWHIGHPLMKW has entered into a definitive business combination agreement with Controll...
2026-03-31
LXEOHIGHLXEO achieved significant clinical milestones with positive interim data and reg...
2026-03-30
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →